Strength Seen in Humana (HUM): Can Its 11.6% Jump Turn into More Strength?

Humana (HUM) shares soared 11.6% in the last trading session to close at $431.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.4% loss over the past four weeks.

Humana stock witnessed a price rise, driven by strength in its Medicare footprint. As of June 30, 2026, the company served 17.9 million medical members, up 20.7% year over year. Individual Medicare Advantage membership increased 23.4% to 6.5 million, while total Medicare membership rose 35.3% to 11.1 million. Its broad membership base, extensive provider networks and longstanding Medicare expertise support market penetration and care coordination capabilities.

Humana's CenterWell platform further strengthens its competitive position by integrating pharmacy, primary care and home health services. During the first half of 2026, CenterWell's external revenues rose 32.2% to $3 billion, supported by 65.7% growth in primary care revenues to $1.6 billion. The company's value-based care model covered approximately 4.1 million individual Medicare Advantage members at June 30, 2026, supporting coordinated care, improved patient outcomes and medical cost management. 

This health insurer is expected to post quarterly loss of $1.04 per share in its upcoming report, which represents a year-over-year change of -132.1%. Revenues are expected to be $40.46 billion, up 23.9% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Humana, the consensus EPS estimate for the quarter has been revised 2.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on HUM going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Humana belongs to the Zacks Medical - HMOs industry. Another stock from the same industry, The Joint Corp. (JYNT), closed the last trading session 1.1% lower at $7.04. Over the past month, JYNT has returned -11.3%.

For The Joint, the consensus EPS estimate for the upcoming report has changed +9.1% over the past month to $0.11. This represents a change of +450% from what the company reported a year ago. The Joint currently has a Zacks Rank of #3 (Hold).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research